Miriplatin Hydrate

米铂水合物

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameMiriplatin Hydrate
Drug Alias Name米铂miriplatinomiriplatine米立铂miriplatinum +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA cross linking agentsDNA synthesis inhibitors
TargetsDNA
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsCarcinoma, Hepatocellular
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2009/10/16
Country/TerritoryJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSumitomo Dainippon Pharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSumitomo Dainippon
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeL01XX
Related LinksKEGG